Study of the Treatment Effects of Compound Tufuling Granules in Hyperuricemic Rats Using Serum Metabolomics

Table 2

Potential related metabolites and their metabolic pathways.

VIP	Compounds	Formula	Retention time	Measured	Adducts type	M∗	Fa^#	B^#	Related pathway
1.26	Galactonic acid	C6H1207	0.65	195.0505	M-H	↑	↓		Pentose and glucuronate interconversions
2.11	Pantothenic acid	C9H17N05	1.71	218.1029	M-H	↑	↓	↓	Pantothenate and CoA biosynthesis
2.13	Orotidine	C10H13N2011P	0.68	287.0516	M-H,2M-H	↑	↓	↓	Pyrimidine metabolism
1.02	Orotic acid	C5H4N204	0.71	155.0094	M-H	↑	↓		Pyrimidine metabolism
12.17	Uric acid	C5H4N403	0.71	167.0207	M-H, 2M-H	↑	↓	↓	Purine metabolism
2.58	Phenylpyruvic acid	C9H803	1.79	163.0397	M-H	↑	↓	↓	Phenylalanine metabolism
4.72	Chenodeoxycholic acid	C02528	4.99	391.285	M-H, 2M-H	↓	↑	↑	Bile secretion

M: model group; N: normal group; Fa: CGT group; B: allopurinol group.
Variable importance in the projection (VIP) was obtained from the OPLS-DA model.
Compared with the N group, ^∗p<0.05.
#Compared with the M group, #p<0.05. ↑, Relative increase in signal; ↓, relative decrease in signal.